- Home
- FMN vs COEP Comparison
FMN vs COEP Comparison
Compare FMN & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMN | COEP |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.8M | 72.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FMN | COEP |
|---|---|---|
| Price | $11.15 | $12.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.3K | ★ 35.4K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.40 | $6.32 |
| 52 Week High | $11.38 | $21.41 |
Technical Indicators
Market Signals| Indicator | FMN | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 57.97 | 52.55 |
| Support Level | $10.97 | $11.76 |
| Resistance Level | $11.29 | $13.23 |
| Average True Range (ATR) | 0.11 | 0.99 |
| MACD | 0.05 | 0.16 |
| Stochastic Oscillator | 83.61 | 75.22 |
Price Performance
Historical ComparisonAbout FMN Federated Hermes Premier Municipal Income Fund
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.